Este sitio requiere JavaScript habilitado para funcionar correctamente. Modifique su configuración o utilice otro navegador para continuar.

Esta usted abandonando la página de GSK.

El enlace le llevará a una página mantenida por un tercero, que es el único responsable de su contenido. GSK no controla, no influencia ni aprueba el sitio. Opiniones, quejas o comentarios expresados en este sitio no deben atribuirse a GSK.

Aceptar

Cancelar

GSK expert recommended sessions at ERS 2022

PREV
NEXT

With more than 400 sessions at the ERS 2022 congress, GSK has asked two experts in chronic obstructive pulmonary disease (COPD) and asthma, to review the whole programme and recommend standout sessions in their fields.

Peter Howarth

ASTHMA (INCLUDING SEVERE ASTHMA)

Professor Peter Howarth

Professor Peter Howarth is Global Clinical Scientific Lead at GSK. He not only identified standout sessions in asthma, but also why he selected each session and who will benefit from attending it.

Paul Jones

COPD

Professor Paul Jones

Professor Paul Jones was the Head of the Division of Clinical Science at St George’s and is a Global Medical Expert for GSK. Professor Jones highlighted the key points in each recommended session, as well as the target audience.

Peter Howarth

Professor Peter Howarth’s recommended sessions for asthma

Peter Howarth is the Global Clinical Scientific Lead at GSK, UK, and Professor Emeritus of Allergy and Respiratory Medicine at the University of Southampton, UK, where he still has ongoing research related to severe asthma.

Sunday 4 September

PAEDIATRICS

8H. Hot topics: Moving to prevention of preschool wheeze and asthma: almost there?

Live streamed 
09:30–11:00 local time

Session covering viral infection as an asthma trigger in pre-school wheeze and asthma, the possible mechanistic benefits of bacterial lysate therapy as an innate immune stimulant and a summary of bacterial lysate therapy clinical studies in children with asthma.

Target Audience
For those interested in or managing preschool wheeze and asthma, to gain an update on the current status with bacterial lysate therapy.

Save to calender

PAEDIATRICS

8H. Symposium: Lung function testing from preschool age to adolescence: are we done with spirometry?

Live streamed
11:15–12:45 local time

Historically, objective measurement of airways disease has centred around spirometry, although its undertaking may present problems in children. This symposium describes developments in spirometry and updates about different approaches to lung function testing that are applicable from preschool age to adolescence, such as oscillometry and the measurement of ventilation heterogeneity.

Target Audience
For those wishing to learn about alternative objective airway measures in children and how they complement or differ from spirometry.

Save to calender

COVID-19

TP-3. Thematic posters: Asthma and COVID-19 management in primary care

08:30–09:30 local time 

Mixture of presentations relating to asthma management and its implementation in the community coupled with those relating to COVID-19 illness and vaccination.

Target Audience
For those managing asthma in the community. 

Save to calender

SEVERE ASTHMA

TP-9. Thematic posters: Asthma treatment: real-world studies and other diseases 

13:00–14:00 local time 

A selection of posters reporting real-world outcome experience, predominantly focusing on severe asthma, and including those relating to biologic therapy.

Target Audience
For those involved in care of patients with severe asthma.

Save to calender

SEVERE ASTHMA

TP-10. Thematic posters: Severe asthma: from phenotypes to exacerbations

13:00–14:00 local time

As described in the title of the session, a medley of posters relating to different aspects of severe asthma. 

Target Audience
Likely to be of some interest to anyone managing patients with severe asthma.  

Save to calender

SEVERE ASTHMA

TP-12. Thematic posters: New insights into asthma immunology: from mouse to man

13:00–14:00 local time

Mechanistic insights into asthma, with focus, although not exclusively so, on severe asthma.

Target Audience
Of interest to anyone dealing with patients with severe asthma and interested in mechanisms of disease.

Save to calender

ASTHMA

TP-13. Thematic posters: Diagnosis, risk factors and management of asthma 

13:00–14:00 local time

Posters covering mild to severe asthma, including topics such as diagnosis, management, epidemiology and economics. 

Target Audience
Very likely to have useful information for anyone with an interest in asthma. 

Save to calender

PAEDIATRICS

TP-15. Thematic posters: Finding the way to a correct asthma diagnosis 

13:00–14:00 local time

A range of posters reporting the use of adjunctive objective measures in the diagnosis of asthma in children.

Target Audience
Valuable insight for anyone involved in paediatric asthma or facing the challenge of diagnosing asthma in a community setting.  

Save to calender

Monday 5 September  

AIRWAY DISEASES

8G. Symposium: Dangers in the air we breathe 

Live streamed
09:30–11:00 local time

Symposium highlighting the current scientific understanding of the effects of airborne pollution factors, especially allergens, diesel exhaust particles, microplastics and microtextiles, on the airways.

Target Audience
For anyone concerned about the current environmental impact of air quality on the airways and its relevance to patients with airways disease, particularly asthma. 

Save to calender

AIRWAY DISEASES

8A. Clinical cases: Lungs on fire: airway diseases?

Live streamed
16:00–17:30 local time 

Real-life clinical cases presented in an interactive session with panel discussion and audience participation, focusing on the diagnosis and treatment of asthma. 

Target Audience
A must for clinicians dealing with difficult asthma.

Save to calender

SEVERE ASTHMA

TP-9. Thematic posters: Studies targeting IL-5 pathways in asthma

08:30–09:30 local time 

Real-life experience of biologics targeting IL-5 or IL-5Rα in severe asthma and relevance of patient characteristics, comorbidities and treatment duration.

Target Audience
The importance of real-life data is evident from these poster presentations and has relevance to all treating patients with biological therapy for asthma.  

Save to calender

AIRWAY DISEASES

TP-10. Thematic posters: Comorbidities in chronic airway diseases

08:30–09:30 local time

Posters of relevance to asthma and COPD, covering healthcare resource utilisation, COVID-19 in airways disease as well as relevance of comorbidity. 

Target Audience
General poster session to dip into if interested in airways disease.

Save to calender

SEVERE ASTHMA

8N. Oral presentation: Clinical and translational studies of asthma and COPD: novel mechanisms 

11:15–12:30 local time 

Mechanistic understanding of asthma and of the effects of biologic therapy in asthma.

Target Audience
Novel insights for those dealing with patients with asthma, particularly severe asthma, and interested in mechanisms of disease.

Save to calender

SEVERE ASTHMA

TP-10. Thematic poster: Asthma biologics in real-life studies 

13:00–14:00 local time

Biologic therapy in severe asthma and real-world outcomes. 

Target Audience
Valuable update on real-world outcomes with biologic therapy in severe asthma for those treating patients with severe asthma.

Save to calender

SEVERE ASTHMA

8L. Oral presentation: New insights into paediatric asthma diagnosis and management of severe asthma 

15:45–17:00 local time

Mechanistic understanding of asthma and of the effects of biologic therapy in asthma in a paediatric population.

Target Audience
Novel insights for paediatricians managing severe asthma and interested in mechanisms of disease.  

Save to calender

Tuesday 6 September

ASTHMA

8H. Primary care session: Asthma diagnosis: new and old approaches to increase primary care capability 

Live streamed
09:30–11:00 local time 

Collective expertise covering the latest approaches to the difficult task of diagnosing asthma in clinical practice.

Target Audience
Valuable session for those working in primary care, providing an update on asthma diagnosis and the potential value of the incorporation of newer measures, such as FeNO and oscillometry.  

Save to calender

DIFFICULT-TO-TREAT ASTHMA

8B. Symposium: Asthma: confusion in diagnosis, recognising comorbidities and understanding pathophysiological connections

Live streamed
14:15–15:45 local time 

Latest updates on conditions that may lead to difficulties with the diagnosis and treatment of asthma, including vocal cord dysfunction and dysfunctional breathing, chronic rhinosinusitis and asthma, asthma as part of a systemic eosinophilic disorder and small airways disease.

Target Audience
A variety of topics all relevant and of interest to those who encounter patients with difficult-to-treat asthma. 

Save to calender

AIRWAY DISEASES

TP-12. Thematic poster: Update on clinical trials in allergy, asthma and COPD

08:30–09:30 local time 

Latest results from clinical trials in upper (rhinitis, CRSwNP) and lower (asthma and COPD) airways disease, including biologic intervention studies. 

Target Audience
A potential opportunity to learn about new developments for those treating patients with airways disease. 

Save to calender

PAEDIATRICS

TP-15. Thematic posters: Paediatric asthma management

08:30–09:30 local time 

A range of posters covering different aspects of paediatric asthma from education to biologic therapy. 

Target Audience
Something for everyone involved in the care of paediatric patients with asthma. 

Save to calender

SEVERE ASTHMA

8L. Oral presentation: Recent advances in biological treatments for asthma 

09:45–11:00 local time

As identified by the title, a session focusing on some of the latest data from biologic therapy in severe asthma.

Target Audience
A session to attend if interested in biologic therapy in severe asthma. 

Save to calender

AIRWAY DISEASES

TP-9. Thematic posters: Translational studies of asthma and COPD

13:00–14:00 local time

Mixture of asthma and COPD posters with some mechanistic and many reporting biologic therapy outcomes in severe asthma.

Target Audience
There should be something of interest in this session for those managing adult patients with airways diseases. 

Save to calender

AIRWAY DISEASES

TP-10. Thematic poster: Clinical treatment of asthma

13:00–14:00 local time

Mainly pharmacological therapy in asthma but not all and majority relating to inhaled therapy but also some covering biological therapy.

Target Audience
General interest to those managing asthma.

Save to calender
Paul Jones

Professor Paul Jones’ recommended sessions for COPD

Paul Jones is Emeritus Professor of Respiratory Medicine at St George’s University of London. He was Head of the Division of Clinical Science at St George’s and a Global Medical Expert for GSK. 

His research now focusses on the effects of lung disease, including COVID-19, on brain microstructure and large cohort studies of chronic obstructive pulmonary disease (COPD) in China and Japan 

Sunday 4 September

AIRWAY DISEASES

8A. State of the art session: Airway diseases

Live streamed
09:30–11:00 local time

A range of topics covering the effect of age on COPD, how chronic cough and pain are related, biomarkers of airways disease in practice and the emerging interest in airway mucus in asthma and COPD.

Target Audience
Will interest clinicians and scientists interested in new concepts in airways disease.

Save to calender

COPD

8B. Hot topics: The future of inhalation therapy in COPD 

Live streamed
16:00–17:30 local time 

A glimpse into the future with talks covering upcoming treatments such as novel bronchodilators, anti-inflammatory drugs, monoclonal antibodies, vaccines and antimicrobials all delivered by the inhaled route.

Target Audience
This will engage anyone interested in future treatments for COPD.

Save to calender

Monday 5 September

COPD

TP-8. Thematic posters: COPD management: comorbidities, cohorts and real-world studies 

08:30–09:30 local time

This thematic poster session includes 20 posters covering a wide range of topics, including identifying exacerbation risk in GOLD A&B, clinically important deterioration in COPD and the incidence of exacerbations pre and post pneumococcal vaccination.

Target Audience
There are posters here for anyone interested in COPD and COPD care.

Save to calender

COPD

8C. Symposium: Treatment of acute respiratory failure in chronic obstructive pulmonary disease patients 

Live streamed
09:30–11:00 local time

Evidence-based recommendations for NIV, use of nasal high-flow oxygen, extracorporeal CO2 removal and long-term outcomes.

Target Audience
Relevant to all clinicians involved in the care of patients with severe COPD exacerbations.

Save to calender

COPD

8A. Symposium: Evolving questions in chronic obstructive pulmonary disease management

Live streamed
14:15–15:45 local time 

Covers a range of topics that address translation from research findings to clinical practice, including eosinophil-based COPD management, definition of COPD exacerbations, applying clinical trial evidence of mortality benefit in routine practice and whether all COPD patients should have plethysmography, CT scans and echocardiograms.

Target Audience
Relevant to all clinicians and researchers interested in near-term developments in COPD management.

Save to calender

Tuesday 6 September

COPD

TP-9. Thematic posters: COPD clinical studies and exacerbations

08:30–09:30 local time 

The majority of papers are concerned with different aspects of inhaled treatment for COPD (not just about treatment efficacy), others report studies about inhalers and a third group focuses on exacerbations.

Target Audience
Not everything will interest everybody, but definitely worth a visit by clinicians and researchers interested in COPD.

Save to calender

COPD IN PRIMARY CARE

8H. Primary care session: Forgotten issues in chronic obstructive pulmonary disease: a primary care perspective

Live streamed
11:15–12:45 local time 

Ignore the ‘primary care’ label it’s for anyone involved in providing COPD rehabilitation. It contains four talks on mental health and sexual health, is home-based rehabilitation the answer for low medium income countries? And a palliative approach to COPD.

Target Audience
Will be stimulating and of value to all clinicians, whether primary or secondary care.

Save to calender

COPD BIOMARKERS

TP-11. Thematic posters: COPD: from biomarkers to phenotypes and severity 

13:00–14:00 local time 

A range of blood and breath biomarker studies, including several with new findings using FeNO and a number on impulse oscillometry.

Target Audience
Clinicians and researchers interested in COPD may find several of these posters to be of interest.

Save to calender

COPD

8B. Hot topics: Towards elimination of COPD

Live streamed
16:00–17:30 local time 

Four talks from the Lancet Commission on COPD. Only the last one addresses the objective in the title, but the other three cover what happens to the patient, revisiting the diagnosis and classification, and unmet treatment needs.

Target Audience
Essential for anyone who wishes to be challenged in their thinking about COPD. 

Save to calender

GSK sponsored website 

UA Agosto 2022: NP-ES-CAU-WCNT-220001(v1)